Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
This study has been terminated.
Study NCT00463762 Information provided by Pfizer
First Received: April 17, 2007 Last Updated: August 23, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Abscess, Intra-Abdominal
Cholecystitis
Wound Infections
Peritonitis
Appendicitis
Additional conditions recognized in this trial
Abdominal Abscess
Acalculous Cholecystitis
Communicable Diseases
Infection
Wound Infection
More general conditions related to this trial
Abscess
Biliary Tract Diseases
Cecal Diseases
Digestive System Diseases
Disorders of Environmental Origin
Gallbladder Diseases
Gastroenteritis
Gastrointestinal Diseases
Intestinal Diseases
Peritoneal Diseases
Suppuration
Wounds and Injuries
Interventions listed in this trial
CP-75385-02 Cefoperazone/sulbactam
Additional drug interventions recognized in this trial
Cefoperazone
Sulbactam
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Pfizer
Back to top of Main Content
